These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10657826)

  • 1. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis.
    Panepinto JA; Magid D; Rewers MJ; Lane PA
    J Pediatr; 2000 Feb; 136(2):201-8. PubMed ID: 10657826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique.
    Grosse SD; Olney RS; Baily MA
    Appl Health Econ Health Policy; 2005; 4(4):239-47. PubMed ID: 16466275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness evaluation of newborn hemoglobinopathy screening from the perspective of state health care systems.
    Gessner BD; Teutsch SM; Shaffer PA
    Early Hum Dev; 1996 Jul; 45(3):257-75. PubMed ID: 8855399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonatal screening for sickle cell disease: a cost-effectiveness analysis.
    Tsevat J; Wong JB; Pauker SG; Steinberg MH
    J Pediatr; 1991 Apr; 118(4 Pt 1):546-54. PubMed ID: 1901081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis.
    Kuznik A; Habib AG; Munube D; Lamorde M
    BMC Health Serv Res; 2016 Jul; 16():304. PubMed ID: 27461265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal screening for sickle cell disease in a metropolitan university hospital: efficacy and problems.
    Ballas SK; Park D; Wapner RJ
    J Med Screen; 1994 Oct; 1(4):229-32. PubMed ID: 8790526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated Cost-effectiveness of Newborn Screening for Congenital Cytomegalovirus Infection in China Using a Markov Model.
    Chen K; Zhong Y; Gu Y; Sharma R; Li M; Zhou J; Wu Y; Gao Y; Qin G
    JAMA Netw Open; 2020 Dec; 3(12):e2023949. PubMed ID: 33275150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of newborn screening for sickle cell disease: a systematic review protocol.
    Mahapatra B; Mukherjee N; Khatoon S; Bhattacharya P; Thubru E; John D
    JBI Evid Synth; 2024 Jun; 22(6):1143-1150. PubMed ID: 38287736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
    Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
    Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is universal neonatal hemoglobinopathy screening cost-effective?
    Sprinkle RH; Hynes DM; Konrad TR
    Arch Pediatr Adolesc Med; 1994 May; 148(5):461-9. PubMed ID: 8180635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of newborn hearing screening strategies.
    Kemper AR; Downs SM
    Arch Pediatr Adolesc Med; 2000 May; 154(5):484-8. PubMed ID: 10807300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population estimates of sickle cell disease in the U.S.
    Hassell KL
    Am J Prev Med; 2010 Apr; 38(4 Suppl):S512-21. PubMed ID: 20331952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Universal and Targeted Newborn Screening for Congenital Cytomegalovirus Infection.
    Gantt S; Dionne F; Kozak FK; Goshen O; Goldfarb DM; Park AH; Boppana SB; Fowler K
    JAMA Pediatr; 2016 Dec; 170(12):1173-1180. PubMed ID: 27723885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MALDI-TOF MS profiling as the first-tier screen for sickle cell disease in neonates: matching throughput to objectives.
    Hachani J; Duban-Deweer S; Pottiez G; Renom G; Flahaut C; Périni JM
    Proteomics Clin Appl; 2011 Aug; 5(7-8):405-14. PubMed ID: 21751410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeted newborn screening for sickle-cell anemia: Sickling test (Emmel test) boundaries in the prenatal assessment in West African area].
    Diallo DA; Guindo A; Touré BA; Sarro YS; Sima M; Tessougué O; Baraika MA; Guindo P; Traoré M; Diallo M; Dorie A
    Rev Epidemiol Sante Publique; 2018 May; 66(3):181-185. PubMed ID: 29625861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Communication of positive newborn screening results for sickle cell disease and sickle cell trait: variation across states.
    Kavanagh PL; Wang CJ; Therrell BL; Sprinz PG; Bauchner H
    Am J Med Genet C Semin Med Genet; 2008 Feb; 148C(1):15-22. PubMed ID: 18200513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).
    Chan K; Davis J; Pai SY; Bonilla FA; Puck JM; Apkon M
    Mol Genet Metab; 2011 Nov; 104(3):383-9. PubMed ID: 21810544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newborn hearing screening: the great omission.
    Mehl AL; Thomson V
    Pediatrics; 1998 Jan; 101(1):E4. PubMed ID: 9417168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and implications of newborn screening for prolongation of QT interval for the prevention of sudden infant death syndrome.
    Zupancic JA; Triedman JK; Alexander M; Walsh EP; Richardson DK; Berul CI
    J Pediatr; 2000 Apr; 136(4):481-9. PubMed ID: 10753246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projected cost-effectiveness of statewide universal newborn hearing screening.
    Keren R; Helfand M; Homer C; McPhillips H; Lieu TA
    Pediatrics; 2002 Nov; 110(5):855-64. PubMed ID: 12415021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.